Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck and Roche form hepatitis C collaboration

Executive Summary

Roche’s Genentech Inc. has agreed to nonexclusively co-promote in the US Merck & Co. Inc.’s newly approved Victrelis (boceprevir) along with peginterferon alfa and ribavirin as a triple therapy for chronic hepatitis C. Presently the standard HCV regimen includes coupling the interferon with ribavirin.

Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)

Related Companies